On the TRAIL toward death receptor-based cancer therapeutics.
Gajewski
Thomas F
TF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D053218:Receptors, Death Domain; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000819:agonists* / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053218:Receptors, Death Domain; D053221:TNF-Related Apoptosis-Inducing Ligand; C507357:mapatumumab